Lincoln [LINCOLN] vs Jagsonpal [JAGSNPHARM] Detailed Stock Comparison

Lincoln Pharmaceuticals Ltd.

NSE
Loading...

Jagsonpal Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lincoln Pharmaceuticals Ltd. wins in 11 metrics, Jagsonpal Pharmaceuticals Ltd. wins in 9 metrics, with 0 ties. Lincoln Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Lincoln Pharmaceuticals Ltd. Jagsonpal Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 13.91 33.34 Lincoln Pharmaceuticals Ltd.
Price-to-Book Ratio 1.71 5.34 Lincoln Pharmaceuticals Ltd.
Debt-to-Equity Ratio 0.01 3.50 Lincoln Pharmaceuticals Ltd.
PEG Ratio 0.37 -0.51 Lincoln Pharmaceuticals Ltd.
EV/EBITDA 9.75 20.20 Lincoln Pharmaceuticals Ltd.
Profit Margin (TTM) 13.47% 14.53% Jagsonpal Pharmaceuticals Ltd.
Operating Margin (TTM) 11.95% 19.03% Jagsonpal Pharmaceuticals Ltd.
EBITDA Margin (TTM) 11.95% 19.03% Jagsonpal Pharmaceuticals Ltd.
Return on Equity 12.26% 23.07% Jagsonpal Pharmaceuticals Ltd.
Return on Assets (TTM) 10.33% 19.90% Jagsonpal Pharmaceuticals Ltd.
Free Cash Flow (TTM) $737.71M $549.52M Lincoln Pharmaceuticals Ltd.
Dividend Yield 0.32% 1.01% Jagsonpal Pharmaceuticals Ltd.
1-Year Return 8.56% -9.26% Lincoln Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.87 4.83 Lincoln Pharmaceuticals Ltd.
Enterprise Value $9.86B $11.62B Jagsonpal Pharmaceuticals Ltd.
EV/Revenue Ratio 1.51 4.13 Lincoln Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 54.33% 63.74% Jagsonpal Pharmaceuticals Ltd.
Revenue per Share (TTM) $325 $42 Lincoln Pharmaceuticals Ltd.
Earnings per Share (Diluted) $43.85 $6.06 Lincoln Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.36 -0.47 Jagsonpal Pharmaceuticals Ltd.

Lincoln Pharmaceuticals Ltd. vs Jagsonpal Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

LINCOLN
JAGSNPHARM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lincoln Pharmaceuticals Ltd.2.65%5.35%1.36%11.75%34.87%36.09%
Jagsonpal Pharmaceuticals Ltd.0.81%7.29%3.34%15.99%6.64%10.68%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lincoln Pharmaceuticals Ltd.8.56%64.45%104.57%356.31%195.59%195.59%
Jagsonpal Pharmaceuticals Ltd.-9.26%40.83%241.72%1,222.84%3,458.75%2,535.79%

Performance & Financial Health Analysis: Lincoln Pharmaceuticals Ltd. vs Jagsonpal Pharmaceuticals Ltd.

MetricLINCOLNJAGSNPHARM
Market Information
Market Cap i₹12.25B₹13.59B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i51,590263,853
90 Day Avg. Volume i43,780325,105
Last Close₹652.95₹213.10
52 Week Range₹440.00 - ₹770.00₹155.00 - ₹301.65
% from 52W High-15.20%-29.36%
All-Time High₹979.50 (Dec 09, 2024)₹328.04 (Nov 25, 2024)
% from All-Time High-33.34%-35.04%
Growth Metrics
Quarterly Revenue Growth0.14%-0.02%
Quarterly Earnings Growth0.38%-0.66%
Financial Health
Profit Margin (TTM) i0.13%0.15%
Operating Margin (TTM) i0.12%0.19%
Return on Equity (TTM) i0.12%0.23%
Debt to Equity (MRQ) i0.013.50
Cash & Liquidity
Book Value per Share (MRQ)₹357.45₹37.80
Cash per Share (MRQ)₹115.79₹24.28
Operating Cash Flow (TTM) i₹967.87M₹532.93M
Levered Free Cash Flow (TTM) i₹823.46M₹553.61M
Dividends
Last 12-Month Dividend Yield i0.32%1.01%
Last 12-Month Dividend i₹1.80₹2.50

Valuation & Enterprise Metrics Analysis: Lincoln Pharmaceuticals Ltd. vs Jagsonpal Pharmaceuticals Ltd.

MetricLINCOLN (Apr 24, 2026)JAGSNPHARM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i13.9133.34
Forward P/E iN/AN/A
PEG Ratio i0.37-0.51
Price to Sales (TTM) i1.874.83
Price to Book (MRQ) i1.715.34
Market Capitalization
Market Capitalization i₹12.25B₹13.59B
Enterprise Value i₹9.86B₹11.62B
Enterprise Value Metrics
Enterprise to Revenue i1.514.13
Enterprise to EBITDA i9.7520.20
Risk & Other Metrics
Beta i0.36-0.47
Book Value per Share (MRQ) i₹357.45₹37.80

Financial Statements Comparison: Lincoln Pharmaceuticals Ltd. vs Jagsonpal Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLINCOLN (2025)JAGSNPHARM (2025)
Revenue/Sales i6.15B2.69B
Cost of Goods Sold i2.93B966.68M
COGS % of Revenue i47.6%36.0%
Gross Profit i3.23B1.72B
Gross Margin i52.4%64.0%
Research & Development iN/AN/A
Operating Income (EBIT) i892.06M429.40M
Operating Margin i14.5%16.0%
EBITDA i1.17B591.61M
EBITDA Margin i19.0%22.0%
Pre-Tax Income i1.09B698.59M
Pre-Tax Income % of Revenue i17.7%26.0%
Income Tax i268.42M144.98M
Income Tax % of Revenue i4.4%5.4%
Net Income (Profit) i823.46M553.61M
Profit Margin i13.4%20.6%

Balance Sheet & Liquidity Metrics

MetricLINCOLN (2025)JAGSNPHARM (2025)
Cash & Equivalents i134.14M112.15M
Total Current Assets i5.00B1.61B
Total Current Assets % of Revenue i81.3%60.0%
Total Current Liabilities i1.06B259.04M
Total Current Liabilities % of Revenue i17.3%9.6%
Long-Term Debt iN/A76.32M
Long-Term Debt % of Revenue i0.0%2.8%
Total Shareholders Equity i6.72B2.40B
Retained Earnings i5.86B1.49B
Retained Earnings % of Revenue i95.2%55.4%
Property, Plant & Equipment i220.84M82.26M

Cash Flow Statement Comparison

MetricLINCOLN (2025)JAGSNPHARM (2025)
Operating Cash Flow i967.87M532.93M
Operating Cash Flow % of Revenue i15.7%19.8%
Capital Expenditures i-189.07M353.70M
Free Cash Flow i737.71M549.52M
FCF Margin i12.0%20.4%
Debt Repayment i-694.17MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLINCOLNJAGSNPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i20.03M67.14M
Float Shares i9.26M16.16M
% Held by Insiders i55.10%75.35%
% Held by Institutions i1.03%2.69%
% Held by Public i43.87%21.96%

Dividend Analysis & Yield Comparison: Lincoln Pharmaceuticals Ltd. vs Jagsonpal Pharmaceuticals Ltd.

MetricLINCOLNJAGSNPHARM
Last 12-Month Dividend i₹1.80₹2.50
Last 12-Month Dividend Yield i0.32%1.01%
3-Year Avg Annual Dividend i₹1.70₹1.37
3-Year Avg Dividend Yield i0.29%0.66%
3-Year Total Dividends i₹5.10₹4.10
Ex-Dividend DateSep 12, 2025Sep 12, 2025